Tissue clearing has been used to map the expression of immune checkpoint molecule PD-L1 and immune cells throughout tumors such as MMTV-HER2/Neu (39, 173) and NSCLC patient resections (174). Here, ERBB2 is linked to non-small cell lung carcinoma.